Compare APRE & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | BNKK |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 11.9M |
| IPO Year | 2019 | N/A |
| Metric | APRE | BNKK |
|---|---|---|
| Price | $0.73 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | 125.6K | ★ 420.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.11 |
| 52 Week High | $2.22 | $7.19 |
| Indicator | APRE | BNKK |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 32.01 |
| Support Level | $0.57 | $0.12 |
| Resistance Level | $0.81 | $2.90 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 15.05 | 13.33 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.